Inhibrx Biosciences (INBX) Other financing activities (2023 - 2025)
Inhibrx Biosciences (INBX) posted quarterly Other financing activities of $1.3 million for Q4 2025, up 256.25% quarter-over-quarter from $352000.0 in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Other financing activities (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Other financing activities for 3 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities changed N/A year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $1.6 million (down 97.76% YoY), while the FY2025 annual figure was $1.6 million, down 97.76% from the prior year.
- Other financing activities rose to $1.3 million in Q4 2025 per INBX's latest filing, from $352000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $198.8 million in Q3 2023 and bottomed at -$197.7 million in Q4 2023.
- Historically, Other financing activities has averaged $12.4 million across 3 years, with a median of $17.1 million in 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.25 Mn |
| Sep 30, 2025 | 352,000.00 |
| Jun 30, 2024 | 32.95 Mn |
| Mar 31, 2024 | 38.73 Mn |
| Sep 30, 2023 | 198.79 Mn |